Outer membrane vesicles as platform vaccine technology
- PMID: 26912077
- PMCID: PMC4768646
- DOI: 10.1002/biot.201400395
Outer membrane vesicles as platform vaccine technology
Abstract
Outer membrane vesicles (OMVs) are released spontaneously during growth by many Gram-negative bacteria. They present a range of surface antigens in a native conformation and have natural properties like immunogenicity, self-adjuvation and uptake by immune cells which make them attractive for application as vaccines against pathogenic bacteria. In particular with Neisseria meningitidis, they have been investigated extensively and an OMV-containing meningococcal vaccine has recently been approved by regulatory agencies. Genetic engineering of the OMV-producing bacteria can be used to improve and expand their usefulness as vaccines. Recent work on meningitis B vaccines shows that OMVs can be modified, such as for lipopolysaccharide reactogenicity, to yield an OMV product that is safe and effective. The overexpression of crucial antigens or simultaneous expression of multiple antigenic variants as well as the expression of heterologous antigens enable expansion of their range of applications. In addition, modifications may increase the yield of OMV production and can be combined with specific production processes to obtain high amounts of well-defined, stable and uniform OMV particle vaccine products. Further improvement can facilitate the development of OMVs as platform vaccine product for multiple applications.
Keywords: Lipopolysaccharide; Neisseria; Outer membrane vesicle; Pertussis; Vaccine.
© 2015 The Authors. Biotechnology Journal published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. The copyright line of the article for this article was changed on 23 February 2016 after original online publication.
Figures

Similar articles
-
Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification.Vaccine. 2019 Nov 8;37(47):6978-6986. doi: 10.1016/j.vaccine.2019.01.076. Epub 2019 Aug 2. Vaccine. 2019. PMID: 31383485
-
Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial.mSphere. 2022 Feb 23;7(1):e0067421. doi: 10.1128/msphere.00674-21. Epub 2022 Jan 26. mSphere. 2022. PMID: 35080470 Free PMC article. Clinical Trial.
-
Outer Membrane Vesicle Vaccine Platforms.BioDrugs. 2024 Jan;38(1):47-59. doi: 10.1007/s40259-023-00627-0. Epub 2023 Oct 5. BioDrugs. 2024. PMID: 37796436 Free PMC article. Review.
-
High dissolved oxygen tension triggers outer membrane vesicle formation by Neisseria meningitidis.Microb Cell Fact. 2018 Oct 3;17(1):157. doi: 10.1186/s12934-018-1007-7. Microb Cell Fact. 2018. PMID: 30285743 Free PMC article.
-
Outer membrane vesicle vaccines.Semin Immunol. 2020 Aug;50:101433. doi: 10.1016/j.smim.2020.101433. Epub 2020 Dec 9. Semin Immunol. 2020. PMID: 33309166 Review.
Cited by
-
Outer Membrane Vesicle Production by Helicobacter pylori Represents an Approach for the Delivery of Virulence Factors CagA, VacA and UreA into Human Gastric Adenocarcinoma (AGS) Cells.Int J Mol Sci. 2021 Apr 11;22(8):3942. doi: 10.3390/ijms22083942. Int J Mol Sci. 2021. PMID: 33920443 Free PMC article.
-
Monoclonal antibodies: From magic bullet to precision weapon.Mol Biomed. 2024 Oct 11;5(1):47. doi: 10.1186/s43556-024-00210-1. Mol Biomed. 2024. PMID: 39390211 Free PMC article. Review.
-
Edible Plant-Derived Extracellular Vesicles for Oral mRNA Vaccine Delivery.Vaccines (Basel). 2024 Feb 15;12(2):200. doi: 10.3390/vaccines12020200. Vaccines (Basel). 2024. PMID: 38400183 Free PMC article. Review.
-
Protein-enriched outer membrane vesicles as a native platform for outer membrane protein studies.Commun Biol. 2018 Apr 5;1:23. doi: 10.1038/s42003-018-0027-5. eCollection 2018. Commun Biol. 2018. PMID: 30271910 Free PMC article.
-
Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy.Theranostics. 2019 Oct 15;9(25):7826-7848. doi: 10.7150/thno.37216. eCollection 2019. Theranostics. 2019. PMID: 31695803 Free PMC article. Review.
References
-
- Lee, E. Y. , Choi, D. Y. , Kim, D. K. , Kim, J. W. et al., Gram‐positive bacteria produce membrane vesicles: Proteomics‐based characterization of Staphylococcus aureus‐derived membrane vesicles. Proteomics 2009, 9, 5425–5436. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical